A new therapy receives regulatory approval. Clinicians see an opportunity for patients who may have exhausted existing options. Inside the hospital, however, approval starts a different conversation.
Can the organization fund it safely? Are pharmacy, nursing, diagnostics, monitoring, and digital workflows ready? Can the system deliver it reliably once the first patient is scheduled?
For hospital leaders, approval is not the same as readiness.
A high-cost treatment can create dependencies across finance, pharmacy, nursing, diagnostics, revenue cycle, governance, and site-of-care planning. Readiness depends on whether those functions can move together.
MDForLives surveyed hospital administrators and executives across the USA, Canada, and Italy to understand where that pathway becomes vulnerable. The detailed findings are available in the MDForLives Hospital Readiness for High-Cost Therapies Insight Report.
Rather than repeating every result, this blog looks at what the findings mean as high-cost therapy moves from approval to real-world delivery.
Before adoption: can the treatment be financially sustained?
The first readiness question comes before acquisition. In the MDForLives survey, 50.0% of hospital leaders said they require strict upfront payer authorization and guaranteed coverage terms before acquiring an extremely high-cost therapy.
Access can fail before the drug reaches the patient. Clinical eligibility and formulary approval do not remove financial risk. High-cost treatment planning therefore needs two checks: is the treatment covered, and is the payment model viable?
In the survey, 37.5% of leaders identified reimbursement rates or ASP markups that fail to cover handling, compounding, and administrative overhead as the most severe onboarding friction.
Across health systems, barriers may involve authorization, reimbursement, formulary restrictions, funding rules, contracts, or site-of-care conditions. Financial uncertainty should be identified before it delays treatment.
This is also where specialty pharmacy management can influence the affordability of high-cost therapies. Acquisition, inventory exposure, cold-chain requirements, reimbursement timing, and patient financial support all affect sustainability.
Before the first patient is scheduled: is the delivery pathway really ready?
Financial clearance is only one gate. A hospital may have approval to offer therapy and still be unprepared to deliver it. The pathway must work from product receipt to administration, monitoring, billing, and follow-up.
The survey highlights workforce capacity: 56.3% of executives identified shortages of appropriately trained nursing staff as the single greatest physical or operational throughput constraint. That shift is planning away from visible infrastructure alone. More infusion chairs do not create capacity if trained nurses are unavailable.
Monitoring creates another dependency. 37.5% of executives said their organization reserves dedicated fast-track diagnostic or imaging slots for specialty-therapy patients. For some high-cost specialty therapies, safety pathways may depend on imaging, laboratory testing, cardiac assessment, or other monitoring within defined windows. Ordinary queues can therefore delay treatment.
Diagnostics can therefore become part of treatment capacity, not merely a supporting service.
The useful question is not simply, “How many patients can this room accommodate?” It is, “What is the scarcest resource across the pathway?”
Implementation planning should follow the patient’s journey: which services must be synchronized, what happens when one is delayed, and who owns the exception.
Strong cross-functional relationships can make that coordination more effective, which is why Networking in Healthcare can support communication between the clinical, operational, and administrative teams involved in therapy delivery
At launch: are pharmacy, digital workflows, and site of care connected?
Once finance, workforce, and monitoring are mapped, launch still depends on infrastructure for both the product and its information flow. 37.5% of executives ranked specialized pharmacy, cold-chain, and point-of-care manufacturing infrastructure as the most critical system investment over the next three to five years.
High-cost treatments may require specialized receiving, storage, preparation, tracking, and handling, while digital systems connect eligibility, authorization, scheduling, monitoring, billing, and reimbursement. A sophisticated pharmacy operation cannot compensate for fragmented financial workflows, while automation cannot solve inadequate product handling.
Health systems also need to decide where that capability should sit. Half of executives surveyed, 50.0%, prioritized dedicated Center of Excellence units at the main hospital campus as their preferred site-of-care strategy.
A centralized model can bring trained teams, pharmacy, diagnostics, finance, monitoring, and governance together while the organization learns the pathway. Physical, digital, and site-of-care planning should therefore be designed together.
As these systems come together, leaders must also consider the ethical issues in healthcare that can arise around equitable access, patient selection, resource allocation, and responsible use of high-cost therapies
As demand grows: can the model scale without adding new risk?
A successful first launch does not automatically mean the therapy is ready to scale. Selected elements may eventually move into ambulatory, community, or home settings, but expansion is easier when the central model is stable.
Before extending access, leaders need to know which capabilities must remain concentrated, and which can safely move outward. Pharmacy, staffing, diagnostics, payer rules, and monitoring may not translate equally well across every site.
This is where the blog differs from the research report. The report shows where executives see pressure. The application question is what the organization should resolve at each launch stage, so growth does not spread unresolved risk. A repeatable launch model can make that easier. If financial gates, workforce requirements, monitoring, pharmacy standards, digital workflows, and governance are defined, each new high-cost treatment does not have to start from zero.
Closing perspective: readiness should be designed before launch
A new therapy tests whether the hospital can coordinate finance, pharmacy, workforce, diagnostics, digital systems, governance, and site of care around one patient journey.
That coordination also depends on maintaining physician autonomy while balancing clinical judgment with the financial and operational realities of treatment delivery
The strongest message is how the risks connect. A therapy can be clinically appropriate but financially uncertain, funded but constrained by nursing, or pharmacy-ready while monitoring remains fragmented.
For hospital leaders, the opportunity is to turn those dependencies into a repeatable launch model. The key questions are consistent: Is funding clear? Are the economics sustainable? Is the workforce ready? Can monitoring happen on time? Can pharmacy manage the product safely? Are digital and revenue-cycle workflows connected? Is the site of care appropriate? Does governance connect those decisions?
Regulatory approval opens the door. Operational readiness determines what happens next.
Frequently Asked Questions
What is considered a high-cost treatment?
A high cost treatment generally refers to a therapy with substantial acquisition and delivery costs, including some specialty medicines, biologics, and cell and gene therapies.
Why are high-cost specialty therapies difficult for hospitals to implement?
The challenge extends beyond drug prices. Hospitals may need funding approval, specialized pharmacy, trained staff, monitoring, revenue-cycle workflows, governance, and an appropriate site of care.
How does specialty pharmacy management influence affordability for high-cost therapies?
Specialty pharmacy management can affect acquisition, inventory exposure, cold-chain handling, contracting, reimbursement, distribution, and financial risk, influencing both sustainability and patient access.
Why does workforce readiness matter for high-cost treatments?
Complex therapies may require specially trained nurses, pharmacists, and diagnostic teams. Physical capacity alone does not create delivery capacity without the required expertise.
What should hospitals assess before launching a newly approved high-cost therapy?
Key areas include funding, reimbursement, pharmacy and cold-chain capability, trained staff, monitoring capacity, site of care, emergency readiness, digital workflows, revenue-cycle processes, and governance.
